Home/ Stocks/ QTTB

Q32 Bio Inc. Common Stock

QTTB XNAS

$15.60 -0.31 (-1.91%) ▼ 15-min delayed

Open

$16.58

High

$16.58

Low

$15.41

Volume

513.5K

Market Cap

$482.18M

About Q32 Bio Inc. Common Stock

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).

Sector: PHARMACEUTICAL PREPARATIONS Employees: 22 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$-246,000	$-8,946,000	$-0.44
Q1 2026	$-192,000	$-7,609,000	$-0.54
FY 2025	$53.74M	$29.82M	$2.42
Q3 2025	$-220,000	$-7,389,000	$-0.60

Related Market News

No specific coverage for QTTB yet. Check out our latest market news or earnings calendar.

Get QTTB Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Q32 Bio Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.